# Agenus Inc. (AGEN) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $6.97, market value $315 million.

## Valuation
- **P/E (trailing): 2.8×**. Agenus Inc. trades at 2.8× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 2.4×**. Each dollar of revenue is priced at 2.4×.
- **EV / EBITDA: 8.7×**. Enterprise value is 8.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: -31.3%** (5-yr avg -93.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 36.3%**. The inverse of the P/E: 36.3% of the price is earned each year.

## Profitability
- **Operating margin: 27.3%**. 27.3% of revenue is left after running the business, an exceptional level.
- **Net margin: -2.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: 1.1%**. 1.1% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: -12.5%**. Return on all capital, debt included, is -12.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 40.5%**. Each dollar of assets produces 40.5% of profit.

## Growth
- **Revenue growth (1 yr): 10.4%** (3-yr 5.2%/yr, 5-yr 5.3%/yr). Revenue grew 10.4% over the last year, against 5.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 100.0%**. Earnings per share rose 100.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 1.0×**. It would take 1.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 0.41** (quick 0.41). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Agenus Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Agenus Inc.; the consensus is strong_buy, with an average price target of $26.33 (+278% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 68.0%** (YTD 112.4%, 3-mo -19.6%). The shares are up 68.0% over twelve months including dividends.
- **From 52-week high: -32.4%** (157.2% above the low). Trading 32% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 1.58** (volatility 120%). Beta of 1.58 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AGEN · Page: https://foliofundamentals.com/stocks/agen

Not investment advice.